First in Human Study of T3P-Y058-739 (T3P)

This study is looking for both men and women aged 18 to 74 who have advanced solid tumours. To be considered, your doctor must confirm that your cancer has been diagnosed through a tissue sample and that there are currently no standard treatments that would cure your condition or are suitable for you. You should also be generally well enough to take part in a study, meaning you can carry out most of your normal daily activities without too much difficulty.

Your recent health and medical history are also important. For example, you should have at least one tumour that can be directly injected, and you must not have certain other serious health issues, such as cancer that has spread to your brain or spinal cord, or a weakened immune system. It's also important that your body's organs, like your kidneys and liver, are working well enough to safely participate.

If you decide to join this study, it's divided into several parts, and your specific journey will depend on which part you are in. Initially, you might receive T3P either as an injection directly into one of your tumours or as a drip into your vein. You would also receive small doses of desferrioxamine, a substance to help the T3P treatment. After your treatment, you will be given antibiotics to clear the T3P from your body.

Throughout the study, you would attend regular appointments for physical examinations, blood tests, and scans (like CT or MRI) to see how your body is reacting to the treatment and whether the tumour is changing. The study involves many hospital visits as it's a new treatment, and the doctors need to monitor you closely. The exact number of visits and the total length of time you'd be involved can vary depending on your treatment response and the study's design. You'll also have a follow-up period after your main treatment to continue monitoring your health.